FIELD: pharmaceuticals.
SUBSTANCE: complex formed from a tetracycline compound (TC) or a pharmaceutically acceptable salt, hydrate or solvate thereof and a divalent metal carboxylate (MA2), in which the TC:MA2 molar ratio is in the range of 1:0.8-3.0, the divalent metal cation M is an alkaline earth metal cation and A is a carboxylate anion derived from a C8-C24 carboxylic acid. The tetracycline (TC) compound is selected from minocycline, doxycycline, chlortetracycline, rolitetracycline, tigecycline, demeclocycline, lymecycline, meclocycline, metacycline, omadacycline, sarecycline, eravacycline, clomocycline, 9-(N,N-dimethylglycilamido)-6-demethyl-6 -deoxytetracycline and 9-(N,N-dimethylglycylamido)minocycline. The invention also relates to a pharmaceutical preparation, methods for obtaining the specified complex and pharmaceutical preparation, the use of the specified complex and a method for treatment using the specified complex or pharmaceutical preparation. The tetracycline compound complexes of the present invention degrade more slowly in aqueous media than the corresponding tetracycline compounds and have lower solubility in water and provide a more delayed and sustained release than the corresponding tetracycline compounds.
EFFECT: proposed complexes can be used for the treatment and/or prevention of bacterial infection or acute, chronic or recurrent periodontal disease.
20 cl, 23 dwg, 4 tbl, 18 ex
Authors
Dates
2023-10-25—Published
2019-10-29—Filed